Item 8.01 - Other Events

On November 17, 2022 Daxor Corporation, the global leader in blood volume measurement technology, announced the closing of its previously announced underwritten public offering consisting of 210,527 shares of its common stock at a public offering price of $9.50 per share. In addition, the underwriter has partially exercised its over-allotment option, purchasing an additional 10,523 shares of common stock at the public offering price, less underwriting discounts and commissions. The aggregate gross proceeds to Daxor from the offering, before deducting the underwriting commissions and other estimated offering expenses payable by Daxor, are expected to be $2.1 million. All of the shares of common stock sold in the offering were offered by Daxor.

Joseph Gunnar & Co., LLC acted as the sole book-running manager for the offering.

Maxim Group LLC acted as an advisor to Daxor Corporation for this transaction

The press release issued is attached to this filing as Exhibit 99.1





Item 9.01 Exhibits

(d) Exhibits. The following exhibit is filed with this Current Report on Form


    8-K:




No.    Description

99.1     Press release dated November 17, 2022 Daxor Corporation Announces Closing
       of $2.1 million Underwritten Public Offering and Exercise of Over-Allotment
       Option

© Edgar Online, source Glimpses